HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa
administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney
disease (CKD)